Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Marc Machaalani, MD, discusses how inhibition of AXL and c-Met may prevent acquired resistance to c-Met inhibitors in renal cell carcinoma.
During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Despite the combo failure, AVEO says that the control arm of Fotivda alone showed statistically significant progression free survival.
A modest survival benefit for interferon alfa therapy in metastatic renal cell carcinoma was observed in two phase III trials comparing interferon ...
Razane El Hajj Chehade, MD, discusses a retrospective study of risk factors for irAEs in patients with metastatic renal cell carcinoma.
Metastatic carcinoma of presumed renal origin (rCUP) has recently emerged as a new entity within the heterogeneous entity of Cancers of Unknown Primary (CUP) but their biological features and optimal therapeutic management remain unknown. We report the molecular characteristics and clinical ...
1 Introduction t(6;11) translocation renal cell carcinoma (t(6;11) (TRCC) has been recognized as a new entity by the International Society of ...
Papillary renal cell carcinoma (pRCC) is a rare kidney cancer with limited treatment options and poor outcomes when metastatic.
Razane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.
Renal cell carcinoma (RCC) is considered radio- and chemo-resistant. Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical efficacy in a...
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.